TAICHUNG, TAIWAN (May 22, 2014) -- Bio-medical Carbon Technology Co., Ltd. (BCT), a leading global wound dressing developer and manufacturer, announced the cooperation with Concord Securities Co., Ltd. (TWSE: 6016) starting from May 21, 2014 to take the BCT public. Biotechnology stocks have recently shown a continuous and strong growth. The trading value of Taiwan’s OTC market has reached an all-time high of NT$16.7 billion (US$554.5 million), and six out of ten most traded and price-gaining stocks were biotechnology companies.
BCT in 2013 received the Class III medical device certification from China Food and Drug Administration (CFDA) for its BCT Silver Bandage, and the Shanghai Municipal Government published the prices in May 2014. This indicates BCT’s silver advanced wound dressings can be legally marketed and sold in all cities and provinces of the People’s Republic of China (PRC).
BCT is also cooperating with many multinational companies in South East Asia, Europe and the U.S. to enter these markets. It is currently conducting clinical trials in the U.K. and planning to roll out its products in the U.S. starting from Q4.
BCT’s silver advanced wound dressings have received many clinical evidences from hospitals in Taiwan and other countries to be proven effective to prevent wound infections, relieve pains and promote wound healing. They are intended for surgical, chronic, burn and diabetic wounds.
About Bio-medical Carbon Technology
Bio-medical Carbon Technology, BCT, develops and manufactures ionic silver coated activated carbon fiber wound care dressings. Its products with proven effectiveness backed by the laboratory tests and clinical trials can treat a broad range of wound types, both acute and chronic wounds. It is proven that its products provide an easy, gentle, faster wound healing. BCT operates worldwide and is supported by its professionals and ongoing development and research. For more information, please visit www.bm-carbon.com